Kerry Pulver, MD
Hematology & Oncology · Boise, IDNPI 1376596247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in ID, where the typical reported total is $2,538.
Across 48 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$124
- E.r. Squibb & Sons, L.L.C.$74
- Novartis$66
- Eisai Inc.$59
- Genentech USA, Inc.$46
- Bristol Myers Squibb$43
- plus $389 from 17 others
Across 84 payments — averaging $9247.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$327K
- Amgen$247K
- Bristol Myers Squibb$66K
- Incyte Corporation$55K
- E.r. Squibb & Sons, L.L.C.$25K
- Cepheid$21K
- plus $37K from 6 others
What the payments were for
- Food & beverage$75394%
- Education$486%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Novartis | 4 | $66 |
| Eisai Inc. | 4 | $59 |
| Genentech USA, Inc. | 3 | $46 |
| Bristol Myers Squibb | 1 | $43 |
| Merck | 3 | $42 |
| Pfizer | 3 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $31 |
| Lilly USA, LLC | 2 | $28 |
| Amgen | 1 | $27 |
| Gilead | 2 | $26 |
| Bayer | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
How this compares
$802 in reported general payments places this provider in the 35th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boise
- Andrew PiersonBoise$4K
- Olga DermanBoise$3K
- Dan ZuckermanBoise$3K
- William KreisleBoise$1K
- Shane AhlersBoise$555
- Nicholas GordenBoise$519
- Zachary BensonBoise$477
- Anuhya KommalapatiBoise$405
- Paul MontgomeryBoise$75
- Andrew DysartBoise$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.